AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients - AstraZeneca (NASDAQ:AZN), AstraZeneca (OTC:AZNCF), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK)

AstraZeneca Plc AZN has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).
The data showed Lynparza plus abiraterone demonstrated improvement in radiographic progression-free survival (rPFS) versus abiraterone as a 1st-line treatment for mCRPC with or without homologous recombination repair (HRR) gene mutations.
Johnson & Johnson's JNJ Zytiga (abiraterone) is considered standard of care.
The trial also showed a trend at this interim analysis towards improved overall survival. However, the data are still immature.
The safety and tolerability were consistent with the known profiles of each medicine.
The data will be presented at an upcoming medical meeting.
In July 2017, AstraZeneca and Merck & Co Inc MRK collaborated to co-develop and co-commercialize Lynparza and Koselugo for multiple cancer types.
Price Action: AZN stock is up 1.87% at $60.59, and MRK stock is up 1.57% at $74.20 during the premarket session on the last check Friday.

AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients